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Abstract
Objectives To quantify the reduction of radiation liver
cancer patients are exposed to during transarterial
chemoembolization (TACE), while maintaining diagnostic
image quality, using a new C-arm imaging platform.
Methods In this prospective, HIPAA-compliant, IRB-ap-
proved, two-arm trial, 78 consecutive patients with primary
or secondary liver cancer were treated with TACE on a C-arm
imaging platform before and after an upgrade incorporating
optimized acquisition parameters and advanced real-time im-
age processing algorithms. Dose area product (DAP) and ra-
diation time of each digital fluoroscopy (DF), digital subtrac-
tion angiography (DSA) and cone beam CT (CBCT) were
recorded. DSA image quality was assessed by two blinded
and independent readers on a four-rank scale.
Results Both cohorts showed no significant differences with
regard to patient characteristics and tumour burden. The new
system resulted in a statistically significant reduction of cu-
mulative DAP of 66 % compared to the old platform (median
132.9 vs. 395.8 Gy cm2). Individually, DAP of DF, DSA and
CBCT decreased by 52 %, 79 % and 15 % (p<0.01, p<0.01,
p=0.51), respectively. No statistically significant differences
in DSA image quality were found between the two imaging
platforms.
Conclusions The new imaging platform significantly reduced
radiation exposure for TACE procedures without increased
radiation time or negative impact on DSA image quality.
Key Points
• The new C-arm system allowed reduction of radiation expo-
sure by two thirds
• The procedure’s course was not affected by the new platform
• No decrease in DSA image quality was observed after the
radiation reduction
Keywords Interventional radiology . Therapeutic
chemoembolization . Liver neoplasms . Radiation dosage .
Cone-beam computed tomography
Introduction
Since the 1950s, the numbers of diagnostic radiographic stud-
ies and image-guided interventional procedures have steadily
increased [1]. In 2004, these diagnostic and therapeutic studies
were the largest source of man-made radiation exposure and
contributed to about 14 % of the total worldwide exposure
from man-made and natural sources [2]. The consequences
of radiation, described as deterministic and stochastic effects,
are of major concern [3, 4]. Following the Bas low as reason-
ably achievable^ (ALARA) principle, there is a balance be-
tween dose reduction and maintaining image quality at a di-
agnostic level [5].
Transarterial chemoembolization (TACE) has become an
important treatment option for a number of primary and sec-
ondary liver malignancies [6–10]. In most patients, TACE is
performed repeatedly because of the multifocal nature of the
disease, incompletely treated lesions or disease recurrence.
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This exposes both patients and clinical staff to high doses of
ionizing radiation [11].
A new X-ray imaging platform (AlluraClarity; Philips
Healthcare, Best, Netherlands) which incorporates optimized
acquisition parameters and several real-time image processing
algorithms with the goal to reduce radiation exposure while
maintaining diagnostic image quality was recently made
available. In the scope of diagnostic and interventional neuro-
radiological procedures, this new platform showed a signifi-
cant radiation exposure reduction of 60 % for the whole pro-
cedure and of 75 % for digital subtraction angiography (DSA)
without a decrease in image quality [12, 13]. In comparison to
neuroradiological procedures, TACE requires a higher tube
current due to the larger field of view and body volume that
needs to be passed by the X-ray photons, resulting in a higher
radiation exposure in the same amount of time. In addition,
abdominal procedures are more prone to motion artefacts,
which could limit the applicability of the real-time image pro-
cessing algorithms of the new imaging platform. Furthermore,
the previously mentioned neuroradiological studies evaluated
only two-dimensional imaging (digital fluoroscopy (DF) and
DSA), and no three-dimensional imaging, such as cone beam
computed tomography (CBCT), which is often performed
during TACE procedures [14].
The purpose of our study was to quantify the reduction of
radiation that liver cancer patients are exposed to during
transarterial chemoembolization (TACE) while maintaining




This prospective, single-institution, two-arm study was con-
ducted in compliance with the Health Insurance Portability
and Accountability Act and was approved by the institutional
review board. In January and February 2014, 26 consecutive
patients with primary or secondary liver cancer treated with
TACE at our institution using the C-arm system (Allura Xper
FD20, Philips Healthcare, Best, the Netherlands) available at
that time were included (control group). The imaging platform
was then upgraded to the new platform (AlluraClarity) and a
second cohort of 52 consecutive patients between March and
June 2014 with liver cancer treated with TACE (study group)
was included. Thus the final population included a total of 78
patients.
MR imaging technique
All patients underwent baseline MR imaging approximately
2 weeks before intra-arterial treatment (mean 16 days, range
0–40) using a 1.5-T MRI unit (Magnetom Avanto, Siemens
Medical Solutions, Forchheim, Germany), using our institu-
tional protocol as previously described [15]. For each patient,
the sagittal abdominal diameter at the level of the portal vein
bifurcation was measured on axial T1-weightedMR images in
the portal-venous phase.
C-arm imaging system
The differences between the two platforms are new acquisi-
tion software protocols for DF and DSA that lower the X-ray
flux, reducing the dose at the cost of decreased image quality,
and a workstation with real-time image processing algorithms
to recover for the loss in image quality. In detail, the new
acquisition parameters consisted of a decreased tube voltage
(75 vs 78 kVp), use of the smaller focal spot size (0.4 vs.
0.7 mm), additional 0.1 mm copper and 1 mm aluminium
filters. Automatic tube current modulation was enabled on
both imaging platforms. The real-time image processing algo-
rithms were spatial noise reduction for DF and spatial noise
reduction, temporal averaging and automatic pixel shift for
DSA [12].
Besides the new acquisition protocols and the real-time
post processing, the two platforms are identical, using a dy-
namic 14-bit flat panel digital detector with an imagematrix of
2480×1920 pixels, a pixel pitch of 154×154 μm and a max-
imum field of view of 30×38 cm.
The dose-saving features apply only to 2D imaging and so
for CBCT, the acquisition parameters and the 3D reconstruc-
tion were identical for both C-arm imaging platforms. The
acquisition parameters for CBCTwere 120 kVp tube voltage,
5 ms exposure and 50 mA tube current, the last of these being
modulated automatically during the acquisition. During 5.2 s
of exposure, 312 projection images (60 frames/s) were ac-
quired with the motorized C-arm covering a 240° clockwise
arc at a rotation speed of up to 55°/s.
TACE protocol
The indication for treatment and the choice of treatment mo-
dality were discussed at our multidisciplinary liver tumor
board on a case-by-case basis. All TACE procedures were
performed by the same interventional radiologist (JFG) with
18 years of experience in hepatic interventions. A standard-
ized approach according to our institutional protocol was used
[16].
A dual-phase C-arm contrast-enhanced CBCT was ac-
quired with the microcatheter placed in the hepatic artery
branch considered to be the main tumour feeding vessel to
verify correct positioning. After drug delivery, a single CBCT
acquisition was performed to confirm technical success of
embolization. Additional details of the CBCT protocols for
identification of feedings arteries and assessment of treatment
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success have been reported previously [14, 15, 17, 18].
CBCTs were not acquired for a few patients who were unable
to hold their breath since acquiring CBCTs with breathing
motion would result in insufficient image quality and would
have been of no clinical value.
Radiation exposure measurements and calculations
The new imaging platform (used for the study group) support-
ed Digital Imaging and Communications in Medicine
(DICOM)Radiation Dose Structured Reports (RDSR). RDSR
contains detailed log information of every X-ray event, in-
cluding radiation time, air kerma (AK), dose area product
(DAP) and number of images acquired (see Appendix 1). A
dedicated workstation was set up with DoseUtility (PixelMed
Publishing, Bangor, PA) to receive, store and evaluate the
RDSRs of the study group patients.
The old imaging platform (used for the control group) did
not support RDSR, thus the examination reports generated by
the system were used (see Appendix 2). These examination
reports contained the AK and the DAP of the whole procedure
as well as the cumulative DAP and radiation time of all DF
runs. However, the DAP of all DSA and CBCT runs was
combined into a single BCumulative DAP (exposure)^ on the-
se examination reports (see Appendix 2). To separate DAP of
DSA and CBCT, the DAP shown on-screen during the treat-
ment before and after each CBCT scan was manually record-
ed. The DAP of each CBCTwas calculated using the follow-
ing formula:
DAP CBCTð Þ ¼ DAP post CBCTð Þ−DAP pre CBCTð Þ
The cumulative DAP of all DSA runs was calculated using
the formula:
Cumulative DAP DSAð Þ
¼ Cumulative DAP exposureð Þ−Cumulative DAP CBCTð Þ
In addition, the examination reports provided only the
number of images acquired and not the radiation time for
DSA. Thus, the latter had to be calculated using the number
of images acquired during each run and knowing the frame
rate used. For example, 30 frames at a frame rate of 3 frames
per second correspond to a radiation time of 10 s. To prove
that all these calculations were correct, examination reports of
five patients undergoing TACE on the new system were also
collected, and the calculated values were found to be the same
as the values recorded using RDSR.
To compensate for the differences in procedure com-
plexity and thus in radiation time between the patients,
the recorded and calculated DAP values were normal-
ized to time by dividing by the corresponding radiation
times for both DF and DSA runs. For example, the
normalized DAP for 1 min of DF was calculated as
DF Cumulative DAP(Gy cm2)/DF radiation time(min).
DF image quality assessment
Objective DF image quality assessment was performed on
an Osirix workstation (Pixmeo, Bernex, Switzerland) by
an interventional radiologist (RES) with more than 4 years
of clinical experience in liver imaging and TACE, who
did not participate in the TACE procedures. For the as-
sessment, a region of interest (ROI) with an area of 3 cm2
was placed in the abdomen, avoiding gas-filled intestines
and bones, and the mean signal intensity and the standard
deviation in Hounsfield units (HU) were recorded. A
signal-to-noise ratio (SNR) was calculated using the for-
mula SNR=meanHU/standarddeviationHU. In addition,
the signal intensity of the guidance wire in HU was re-
corded and a contrast ratio (CR) was calculated with the
formula CR=meanHU/guidancewireHU.
DSA image quality assessment
Qualitative DSA image analysis was performed by two inter-
ventional radiologists (RES and RD), each with more than
4 years of clinical experience in liver imaging and TACE,
who did not participate in the TACE procedures. The DSA
images of the celiac run of all patients were presented in a
blinded and randomized fashion on an Osirix workstation.
The readers were blinded to the imaging C-arm system used
and the imaging parameters. The window/level settings used
were maintained as the default settings in Osirix. Both readers
determined independently in separate reading sessions the vis-
ibility of the hepatic arteries using a four-point grading score
(Table 1).
Statistical analysis
All statistical computations were performed in SPSS Statistics
22 (IBM Corp., Armonk, NY). A p value less than 0.05 was
considered statistically significant. Descriptive statistics were
Table 1 Four-point grading score for the subjective assessment of DSA
image quality
Score Description
1 Perfect visualization of all hepatic arteries
including small intra-tumoral vessels
2 Visibility from the proper hepatic artery to
the subsegmental branches
3 Visibility from the proper hepatic artery to
the segmental branches
4 Visibility from the proper hepatic artery to
the lobar arteries only
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performed to summarize the data. The distribution of all
scale variables was assessed with the Shapiro–Wilk test.
For scale variables with normal distribution, mean, stan-
dard deviation and range were used and an unpaired t
test was performed. For scale variables with non-
Gaussian distribution, median, interquartile range and
range were used and a Wilcoxon rank-sum test was
performed. For ordinal variables, count and percentage
were used and a Wilcoxon rank-sum test was per-




Patients’ baseline characteristics are summarized in
Table 2. There was no significant difference between the
study and the control groups regarding age (p=0.71), BMI
(p=0.95) and sagittal abdominal diameter of the patient at
the level of the portal vein bifurcation (p=0.69). Hepato-
cellular carcinoma was the most common cancer in both
groups, tumour burden by means of lesion number and
number of affected liver segments were similar (p=0.49
and p=0.34, respectively).
TACE procedures
Procedure characteristics are summarized in Table 3. Approx-
imately half of the procedures were for TACE-naïve patients
in both cohorts. Conventional TACE was performed in the
majority of cases (56 % and 73 % of the study and control
groups, respectively). However, only a minority of procedures
were performed in a lobar fashion (21% and 15% of the study
and control groups, respectively). The median DF time for
study and control groups was 15.6 min (range 5.6–37.2) and
15.5 min (range 8.6–54.6), respectively. A median of 6 DSA
runs was acquired in the study (range 3–11) and control (range
3–13) groups, respectively. The median DSA time for study
and control groups was 71.5 s (range 17.4–167.4) and 63.9 s
(range 24.4–204.2). Amedian of 3 CBCTs was acquired in the
study (range 0–5) and control (range 0–6) groups, respective-
ly. There were no statistically significant differences between
the two groups regarding DF time (p=0.34), DSA time (p=
0.66) as well as number of DSA and CBCT performed (p=
0.97 and p=0.56, respectively).
Radiation exposure
A detailed description of DAP and AK in terms of median,
interquartile range, minimum and maximum is summarized
for the study and the control groups in Table 4, including the
Table 2 Baseline characteristics
of the study and the control
groups
Characteristic Study group Control group p value
No. of patients 52 (100) 26 (100)
Sex
Female 15 (29) 5 (19)
Male 37 (71) 21 (81)
Agea 60.3±10.8 (33–79) 61.3±10.5 (33–80) 0.71
Body mass indexa 27.5±5.9 (16.0–40.9) 27.4±6.1 (16.0–37.9) 0.95
Sagittal abdominal diameter at the
level of the portal vein bifurcation (cm)a
25.6±4.1 (18.2–36.7) 25.2±4.0 (18.3–31.2) 0.69
Tumour type
Hepatocellular carcinoma 32 (61) 20 (77)
Intrahepatic cholangiocarcinoma 3 (6) 1 (4)
Secondary liver cancer 17 (33) 5 (19)
No. of lesions 0.49
1 13 (25) 9 (35)
2 8 (15) 4 (15)
3 8 (15) 4 (15)
>3 23 (45) 9 (35)
No. of segments affected 0.34
1 or 2 24 (46) 14 (54)
3 or 4 9 (17) 3 (12)
>4 19 (37) 9 (35)
Except where indicated, data represent numbers of patients and numbers in parentheses are percentages
a Data represented as mean±standard deviation (range)
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values normalized by radiation time. By switching to the
new system, the cumulative DAP and the cumulative AK
decreased by 66 % (from 395.8 to 132.9 Gy cm2) and
61 % (from 1.16 to 0.49 Gy), respectively. The DAP for
DF and for exposure (DSA and CBCT) decreased by
52 % (from 99.6 to 47.8 Gy cm2) and 70 % (from 272.6
to 81.8 Gy cm2), respectively. The DAP reduction for
CBCT was only 15 %, whereas for DSA it was 79 %
(Fig. 1). After normalizing DF and DSA by the radiation
time, the DAP for DF and DSA decreased by 47 % (from
6.4 to 3.4 Gy cm2/min) and 84 % (from 244.7 to
39.9 Gy cm2/min), respectively. In the control group, DF
and DSA accounted for 27 % and 61 % of the cumulative
DAP, respectively. In the study group, the contribution of
DF increased to 38 %, whereas the contribution of DSA
to the cumulative DAP decreased to 38 %. Most impor-
tantly, the relative contribution of CBCT to the cumula-
tive DAP increased from 12 % to 24 % by switching to
Table 3 Procedure
characteristics of the study and
the control groups
Characteristic Study group Control group p value
Sequence no. of procedure 0.62
1 25 (48) 11 (42)
2 14 (27) 7 (27)
3 5 (10) 3 (12)
>3 8 (15) 5 (19)
Type of TACE
Conventional TACE 29 (56) 19 (73)
Drug-eluting beads TACE 23 (44) 7 (27)
Selectivity of TACE
Lobar 11 (21) 4 (15)
Selective 16 (31) 10 (38)
Superselective 25 (48) 12 (46)
Catheter positions for drug delivery 0.69
1 40 (77) 19 (73)
2 12 (23) 7 (27)
DF time (min)a 15.6; 9.8 (5.6–37.2) 15.5; 11.0 (8.6–54.6) 0.34
No. of DSA acquisitionsa 6; 3.8 (3–11) 6; 3.0 (3–13) 0.97
DSA time (s)a 71.5; 48.0 (17.4–167.4) 63.9; 35.3 (24.4–204.2) 0.66
No. of CBCT acquisitionsa 3; 2 (0–5) 3; 1 (0–6) 0.56
Except where indicated, data represent numbers of patients and numbers in parentheses are percentages
a Data represented as median; interquartile range (range)
Table 4 Radiation exposure for
the study and the control groups Study group Control group Reduction p value





Cumulative AK (Gy) 0.49; 0.52 (0.06–2.35) 1.16; 1.18 (0.28–3.82) 61 % <0.01





DF DAP/min (Gy cm2/min) 3.4; 3.7 (1.1–15.3) 6.4; 5.2 (2.2–12.0) 47 % <0.01





CBCT DAP for 1 CBCT
(Gy cm2)





44.8; 40.7 (0.0-82.4) 32 % 0.19










Data represented as median; interquartile range (range)
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the new system. In other words, the radiation exposure of
one CBCT was equivalent to 155 s DF or 4 s DSA in the
control group and 247 s DF or 21 s DSA in the study
group.
DF image quality
The SNR of the new platform was significantly higher than
that of the old platform [31.1±6.0 (range 17.7–49.9) vs 23.2±
4.4 (range 15.7–31.8); p<0.01]. The visibility of the guide
wire expressed as CR on the other hand was significantly
lower in the new platform [1.74±0.35 (range 1.27–2.63) vs
2.00±0.30 (range 1.46–2.50); p≤0.01].
DSA image quality
There was no statistically significant difference regarding the
image quality between the two cohorts according to both
readers (p=0.82 and p=0.75, respectively) using the provided
four-point grading score for the visibility of hepatic arteries.
Both readers rated the majority of celiac arteriograms in both
cohorts as perfect (category 1) (Fig. 2). No celiac arteriogram
was rated as category 4 (Table 5). Cohen’s kappa showed a
substantial agreement between both readers (κ=0.76 and κ=
0.66 for the old and new platforms, respectively, p<0.01). A
detailed distribution of image quality scores is shown in
Table 5.
Fig. 1 Box plot showing the
distribution of radiation exposure
(dose area product in Gy cm2) for
the study and the control groups
for the entire procedure, for
digital subtraction angiography,
digital fluoroscopy and cone
beam CT. The plot uses power
scale on the y-axis and shows the
interquartile range (box), 5th and
95th percentiles (outermost bars)
and the median (thick horizontal
line) of the exposure distribution
in each system
Fig. 2 Celiac arteriogram during
TACE in two patients with
neuroendocrine tumour. Left
panel was acquired on the
preceding imaging platform and
the right panel on the new
imaging platform. Both
arteriograms were of diagnostic
quality, showing the tumour-
feeding arteries and the tumour
blush (arrowheads). However,
the new imaging platform
resulted in a significantly lower
radiation exposure during the
acquisition of the celiac
arteriogram
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Discussion
The main finding of our study was the significant radiation
exposure reduction of up to 66 % for the entire TACE proce-
dure as a result of the new imaging platform. This significant
reduction in radiation exposure is especially important in pa-
tients being treated repeatedly with TACE, in similar therapies
such as radio-embolization, or as a bridging or downstaging
prior to liver transplantation [19]. Furthermore, the reduction
in radiation exposure using the new system is also of impor-
tance for the in-room medical staff, because they are exposed
to radiation on a regular basis.
Of note, the radiation exposure reduction was only signif-
icant for two-dimensional runs (such as DF and DSA) and not
for CBCT acquisitions. This was expected as the dose reduc-
tion techniques in our work apply for 2D imaging only. The
DSA runs showed the highest radiation exposure reduction of
up to 84 %, and the exposure during DF and CBCT runs
decreased by 47 % and 15 %, respectively. Thus, the relative
impact of DSA on the cumulative DAP decreased from 61 %
to 38 %, and the relative impact of DF and CBCT increased
from 27 to 38 % and from 12 % to 24 %, respectively. Given
the steady increase in the use of CBCT in TACE procedures
because of its proven benefits [20–26], dose reduction for this
imaging modality should be the next logical step to decrease
cumulative radiation exposure even further.
Another important finding was that the image quality of
DSA runs bymeans of subjective assessment of hepatic vessel
visualization was not affected by the significant reduction of
radiation exposure. For DF runs, the new platform showed a
significantly improved SNR at the cost of a significantly de-
creased CR, in comparison to the old platform. However, the
DF radiation time did not increase, clearly showing that this
objectively measured difference in DF image quality did not
have a negative impact on the course of TACE procedures. In
other words, the image quality was still sufficient to continue
the TACE procedure.
Comparison with other studies using absolute numbers is
difficult because different metrics were used. Paul et al. [27]
used peak skin dose and DAP to compare three generations of
angiographic imaging systems. These authors reported a radi-
ation exposure reduction of 62 %, 15 % and 49 % for DF,
DSA and CBCT during TACE procedures, respectively. The
main reason for the significant reduction of CBCT DAP in
their study was a faster CBCT acquisition protocol (3 vs. 8 s),
which also resulted in fewer projection images being acquired
(133 vs. 382 frames). However, their mean DAP for a CBCT
run was 21.58 Gy cm2, whereas our CBCT protocol resulted
in a median DAP of 13.9 Gy cm2 with 5.2 s of radiation time
(the same acquisition protocol was used for both control and
study imaging platforms). In addition, most studies do not
normalize their exposure measurements by the radiation time,
but only report radiation exposure and time as separate values.
In our study, radiation exposure and time values were used
together to calculate DF and DSA DAP for 1 min of radiation
time each to normalize for differences in procedure complex-
ity and to enable a better comparison with other studies. We
report a median DF and DSA DAP per minute of 3.4 and
39.9 Gy cm2 on the new imaging platform, respectively. Cal-
culating these normalized values for the previously mentioned
study [27], their mean DF and DSA DAP were 5.8 and
92.9 Gy cm2 on the latest generation of imaging platform
used, respectively. This underlines the substantial radiation
exposure reduction achieved by the new imaging platform
used in our study.
Our study had several limitations. First, the number of pa-
tients included in the control group was limited to 26 by the
upgrade of the imaging platform. However, even with a rela-
tively small sample size of 78 patients, a statistically signifi-
cant radiation exposure reduction was achieved while the
study and the control groups did not show any significant
differences in patient characteristics and in radiation time.
Second, RDSR was not available for the preceding imaging
platform, thus manual exposure logging had to be performed
for all patients undergoing TACE on that platform and the
DSA radiation time was calculated retrospectively using the
number of images acquired during each DSA run. However,
these calculations were verified by comparison to RDSR for a
subset of patients examined on the new imaging platform.
In conclusion, the new imaging platform significantly re-
duced radiation exposure for TACE procedures without in-
creased radiation time or negative impact on image quality.
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